Download PDF
Am J Perinatol 2010; 27(5): 425-429
DOI: 10.1055/s-0029-1243371
© Thieme Medical Publishers

Safety and Effectiveness of Indomethacin versus Ibuprofen for Treatment of Patent Ductus Arteriosus

Lakshmi I. Katakam1 , C. Michael Cotten1 , Ronald N. Goldberg1 , Chi N. Dang1 , P. Brian Smith1 , 2
  • 1Department of Pediatrics, Duke University Medical Center, Durham, North Carolina
  • 2Duke Clinical Research Institute, Durham, North Carolina
Further Information

Publication History

Publication Date:
11 December 2009 (online)

Also available at
    Permissions and Reprints

ABSTRACT

We compared the rates of medical closure of patent ductus arteriosus (PDA) and complications (renal dysfunction, necrotizing enterocolitis, spontaneous intestinal perforation, and intraventricular hemorrhage) between infants treated with indomethacin and infants treated with ibuprofen. We performed a retrospective comparative cohort study of infants treated with indomethacin or ibuprofen for symptomatic PDA at Duke University Medical Center between November 2005 and November 2007. We identified 65 infants who received indomethacin and 57 who received ibuprofen. The rate of survival without surgical ductal ligation was 62% (40/65) in the indomethacin group and 58% (33/57) in the ibuprofen group (p = 0.71). The rate of the composite of complications (death, necrotizing enterocolitis, or intestinal perforation) was 40% (26/65) in the indomethacin group and 32% (18/57) in the ibuprofen group (p = 0.35). There was no significant difference between groups in elevation of serum creatinine during treatment. In clinical practice, ibuprofen appears to be as effective as indomethacin for closure of patent ductus arteriosus with similar complication rates. The decision to use one agent over the other should be based on dose schedule preference and the currently published clinical trials until more safety and effectiveness data are available.

KEYWORDS

Ibuprofen - indomethacin - patent ductus arteriosus - neonates - nonsteroidal anti-inflammatory drug

REFERENCES

  • 1 Poon G. Ibuprofen lysine (NeoProfen) for the treatment of patent ductus arteriosus.  Proc (Bayl Univ Med Cent). 2007;  20 83-85
    PubMedSearch in Google Scholar
  • 2 Aranda J V, Clyman R, Cox B et al.. A randomized, double-blind, placebo-controlled trial on intravenous ibuprofen L-lysine for the early closure of nonsymptomatic patent ductus arteriosus within 72 hours of birth in extremely low-birth-weight infants.  Am J Perinatol. 2009;  26 235-245
    Thieme ConnectPubMedSearch in Google Scholar
  • 3 Aranda J V, Thomas R. Systematic review: intravenous ibuprofen in preterm newborns.  Semin Perinatol. 2006;  30 114-120
    CrossrefPubMedSearch in Google Scholar
  • 4 Gimeno Navarro A, Cano Sánchez A, Fernández Gilino C et al.. [Ibuprofen versus indomethacin in the treatment of patent ductus arteriosus in preterm infants].  An Pediatr (Barc). 2005;  63 212-218
    CrossrefPubMedSearch in Google Scholar
  • 5 Lago P, Bettiol T, Salvadori S et al.. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial.  Eur J Pediatr. 2002;  161 202-207
    CrossrefPubMedSearch in Google Scholar
  • 6 Sangtawesin C, Sangtawesin V, Lertsutthiwong W, Kanjanapattanakul W, Khorana M, Ayudhaya J K. Prophylaxis of symptomatic patent ductus arteriosus with oral ibuprofen in very low birth weight infants.  J Med Assoc Thai. 2008;  91(Suppl 3) S28-S34
    PubMedSearch in Google Scholar
  • 7 Sekar K C, Corff K E. Treatment of patent ductus arteriosus: indomethacin or ibuprofen?.  J Perinatol. 2008;  28(Suppl 1) S60-S62
    CrossrefPubMedSearch in Google Scholar
  • 8 Su B H, Lin H C, Chiu H Y, Hsieh H Y, Chen H H, Tsai Y C. Comparison of ibuprofen and indomethacin for early-targeted treatment of patent ductus arteriosus in extremely premature infants: a randomised controlled trial.  Arch Dis Child Fetal Neonatal Ed. 2008;  93 F94-F99
    PubMedSearch in Google Scholar
  • 9 Van Overmeire B, Smets K, Lecoutere D et al.. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus.  N Engl J Med. 2000;  343 674-681
    CrossrefPubMedSearch in Google Scholar
  • 10 Jobe A H. Drug pricing in pediatrics: the egregious example of indomethacin.  Pediatrics. 2007;  119 1197-1198
    CrossrefPubMedSearch in Google Scholar
  • 11 Van Overmeire B, Follens I, Hartmann S, Creten W L, Van Acker K J. Treatment of patent ductus arteriosus with ibuprofen.  Arch Dis Child Fetal Neonatal Ed. 1997;  76 F179-F184
    CrossrefPubMedSearch in Google Scholar
  • 12 Ohlsson A, Walia R, Shah S. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants.  Cochrane Database Syst Rev. 2008;  (1) CD003481
    PubMedSearch in Google Scholar
  • 13 Watterberg K L, Gerdes J S, Cole C H et al.. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial.  Pediatrics. 2004;  114 1649-1657
    Search in Google Scholar
  • 14 Pezzati M, Vangi V, Biagiotti R, Bertini G, Cianciulli D, Rubaltelli F F. Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus.  J Pediatr. 1999;  135 733-738
    CrossrefPubMedSearch in Google Scholar
  • 15 Plavka R, Svihovec P, Biolek J et al.. Ibuprofen vs. indomethacin in the treatment of patent ductus arteriosus (PDA) in very premature neonates.  Pediatr Res. 2001;  49 375A
    PubMedSearch in Google Scholar
  • 16 Giniger R P, Buffat C, Millet V, Simeoni U. Renal effects of ibuprofen for the treatment of patent ductus arteriosus in premature infants.  J Matern Fetal Neonatal Med. 2007;  20 275-283
    CrossrefPubMedSearch in Google Scholar

P. Brian Smith

Duke Clinical Research Institute

PO Box 17969, Durham, NC 27715

Email: brian.smith@duke.edu